HONG KONG – Malaysia-based CCM Duopharma Biotech Bhd is positioning itself to capitalize on the growing biosimilars market in Southeast Asia (SEA), following the success of a phase III trial of its erythropoietin (EPO) biosimilar for kidney dialysis. The Kuala Lumpur-based company is set to commence registration of the drug and further strengthen its position in the Malaysian market.
HONG KONG – Reforms to China’s drug approval process are gradually changing the industry, but the reforms are not making things easier for multinational drugmakers looking to launch new medicines in the country.
HONG KONG – China has added more than 300 new drugs to the National Reimbursement Drug List (NRDL) in its latest revision released Friday – the first since 2009.
HONG KONG – China has added more than 300 new drugs to the National Reimbursement Drug List (NRDL) in its latest revision released Friday – the first since 2009.
HONG KONG – Reforms to China's drug approval process are gradually changing the industry, but the reforms are not making things easier for multinational drugmakers looking to launch new medicines in the country.
HONG KONG – Imminent changes to Taiwan's drug approval process could dramatically improve the country's pharmaceutical sector, potentially shortening approval times and boosting growth. Drug developers operating in the country are paying close attention to upcoming reforms, which should be implemented soon.
